Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD. We are able to demonstrate a reduction in non-motor...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/12/5/661 |
| _version_ | 1797501149070229504 |
|---|---|
| author | Philipp Ellmerer Marina Peball Federico Carbone Marcel Ritter Beatrice Heim Kathrin Marini Dora Valent Florian Krismer Werner Poewe Atbin Djamshidian Klaus Seppi |
| author_facet | Philipp Ellmerer Marina Peball Federico Carbone Marcel Ritter Beatrice Heim Kathrin Marini Dora Valent Florian Krismer Werner Poewe Atbin Djamshidian Klaus Seppi |
| author_sort | Philipp Ellmerer |
| collection | DOAJ |
| description | The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD. We are able to demonstrate a reduction in non-motor symptom (NMS) burden after the administration of nabilone. As impairment of attention and working memory have been described earlier as possible side effects, we assess cognitive performance using saccadic paradigms measured by an eye tracker. We do not observe a significant difference in any of the saccadic paradigms between PD patients on placebo versus those treated with nabilone. We, therefore, conclude that top-down inhibitory control is not affected by the tetrahydrocannabinol analogue. Nabilone did not significantly worsen cognitive performance and appears to be safe to use in selected PD patients who suffer from disabling NMS. |
| first_indexed | 2024-03-10T03:14:12Z |
| format | Article |
| id | doaj.art-06fbd6a3fb4247819484ed151d5700ca |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-10T03:14:12Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-06fbd6a3fb4247819484ed151d5700ca2023-11-23T10:18:37ZengMDPI AGBrain Sciences2076-34252022-05-0112566110.3390/brainsci12050661Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot StudyPhilipp Ellmerer0Marina Peball1Federico Carbone2Marcel Ritter3Beatrice Heim4Kathrin Marini5Dora Valent6Florian Krismer7Werner Poewe8Atbin Djamshidian9Klaus Seppi10Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaInteractive Graphics and Simulation Group, University of Innsbruck, Innrain 52, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, AustriaThe topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD. We are able to demonstrate a reduction in non-motor symptom (NMS) burden after the administration of nabilone. As impairment of attention and working memory have been described earlier as possible side effects, we assess cognitive performance using saccadic paradigms measured by an eye tracker. We do not observe a significant difference in any of the saccadic paradigms between PD patients on placebo versus those treated with nabilone. We, therefore, conclude that top-down inhibitory control is not affected by the tetrahydrocannabinol analogue. Nabilone did not significantly worsen cognitive performance and appears to be safe to use in selected PD patients who suffer from disabling NMS.https://www.mdpi.com/2076-3425/12/5/661Parkinson’s diseasenabilonecannabiseye-trackingnon-motor symptoms |
| spellingShingle | Philipp Ellmerer Marina Peball Federico Carbone Marcel Ritter Beatrice Heim Kathrin Marini Dora Valent Florian Krismer Werner Poewe Atbin Djamshidian Klaus Seppi Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study Brain Sciences Parkinson’s disease nabilone cannabis eye-tracking non-motor symptoms |
| title | Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study |
| title_full | Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study |
| title_fullStr | Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study |
| title_full_unstemmed | Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study |
| title_short | Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study |
| title_sort | eye tracking in patients with parkinson s disease treated with nabilone results of a phase ii placebo controlled double blind parallel group pilot study |
| topic | Parkinson’s disease nabilone cannabis eye-tracking non-motor symptoms |
| url | https://www.mdpi.com/2076-3425/12/5/661 |
| work_keys_str_mv | AT philippellmerer eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT marinapeball eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT federicocarbone eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT marcelritter eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT beatriceheim eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT kathrinmarini eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT doravalent eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT floriankrismer eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT wernerpoewe eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT atbindjamshidian eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy AT klausseppi eyetrackinginpatientswithparkinsonsdiseasetreatedwithnabiloneresultsofaphaseiiplacebocontrolleddoubleblindparallelgrouppilotstudy |